Aim: ALK, ROS1, NTRK and RET gene fusions and MET exon 14 skipping alterations represent novel predictive biomarkers for advanced non-small-cell lung cancer (NSCLC). Therefore, testing patients for these genetic variants is crucial for choosing the best selective treatment. Over the last couple of decades, next generation sequencing (NGS) platforms have emerged as an extremely useful tool for detecting these variants. Materials & methods: In the present study, we report our NGS molecular records produced during a year of diagnostic activity. Results: Overall, our in-house developed NGS workflow successfully analyzed n = 116/131 (88.5%) NSCLC samples. Of these, eight (6.8%) and five (4.3%) out of 116 patients harbored ALK and RET gene rearrangements, respectively: one case harbored ROS1 gene fusion (0.7%). Conclusion: Our results highlight that an RNA-based NGS analysis can reliably detect gene fusion alterations, thereby playing a pivotal role in the management of NSCLC patients.
RNA-based next generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center / DE LUCA, Caterina; Pepe, Francesco; Pisapia, Pasquale; Iaccarino, Antonino; Righi, Luisella; Listì, Angela; Russo, Gianluca; Campione, Severo; Pagni, Fabio; Nacchio, Mariantonia; Conticelli, Floriana; Russo, Maria; Fabozzi, Teresa; Vigliar, Elena; Bellevicine, Claudio; Rocco, Danilo; Laudati, Stefano; Iannaci, Giuseppe; Daniele, Bruno; Gridelli, Cesare; Luigi Cortinovis, Diego; Novello, Silvia; Angel Molina-Vila, Miguel; Rosell, Rafael; Troncone, Giancarlo; Malapelle, Umberto. - In: PERSONALIZED MEDICINE. - ISSN 1741-0541. - (2022). [10.2217/pme-2022-0020]
RNA-based next generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center
Caterina De Luca;Francesco Pepe;Pasquale Pisapia;Antonino Iaccarino;Gianluca Russo;Severo Campione;Mariantonia Nacchio;Floriana Conticelli;Maria Russo;Elena Vigliar;Claudio Bellevicine;Giancarlo Troncone;Umberto Malapelle
2022
Abstract
Aim: ALK, ROS1, NTRK and RET gene fusions and MET exon 14 skipping alterations represent novel predictive biomarkers for advanced non-small-cell lung cancer (NSCLC). Therefore, testing patients for these genetic variants is crucial for choosing the best selective treatment. Over the last couple of decades, next generation sequencing (NGS) platforms have emerged as an extremely useful tool for detecting these variants. Materials & methods: In the present study, we report our NGS molecular records produced during a year of diagnostic activity. Results: Overall, our in-house developed NGS workflow successfully analyzed n = 116/131 (88.5%) NSCLC samples. Of these, eight (6.8%) and five (4.3%) out of 116 patients harbored ALK and RET gene rearrangements, respectively: one case harbored ROS1 gene fusion (0.7%). Conclusion: Our results highlight that an RNA-based NGS analysis can reliably detect gene fusion alterations, thereby playing a pivotal role in the management of NSCLC patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
